Could a stroke drug help dementia patients?

NCT ID NCT03804229

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 3 trial tests whether butylphthalide soft capsules can improve thinking, memory, and daily living skills in people with mild to moderate vascular dementia. About 707 participants are randomly assigned to receive either the drug or a placebo for 52 weeks. The study aims to confirm earlier promising results from a Phase 2 trial.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Butylphthalide soft capsule

What this could lead to

If successful, this could provide a new treatment option to slow cognitive decline and improve daily function in people with vascular dementia.

What could go wrong

This is a Phase 3 trial, but results are not yet published. The drug may not show significant benefit over placebo, and side effects are possible.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for VASCULAR DEMENTIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

vascular dementia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Xuanwu Hospital of Capital Medical University

    Beijing, Beijing Municipality, 100053, China